About Event

Why Attend the 7th Antigen-Specific Immune Tolerance Summit (ASIT)?

Returing for the seventh year, the 7th Antigen-Specific Immune Tolerance Summit will lean into the industry’s key challenges from details of T-cell assays in preclinical and larger clinical studies; to pioneering CAR-Treg, mRNA-LNP, biologic, peptide, approaches and updates on proof-of-concept and ongoing clinical programs. This is the highest value meeting on the immune tolerance community’s conference calendar. 

This is your comprehensive guide to define your pipeline and therapeutic development strategy for 2023, delve into your opportunity to create tolerizing, curative, strategies for autoimmunity, and tap into your tolerance strategy to tackle immunogenicity and transform the biologic landscape. Network with large pharma scouts, industry super-giants, and biotech pioneers to build meaningful partnerships and gather insights beyond the literature.  

 

Expect To Be Involved in Interactive Discussions On:

graphic background - no.1

Tackle antigen-selection and deepen your understanding of the role of
T-cells, B-cells and T-regs
 in immune tolerance evaluate strategies and technologies in complex heterogenous disease settings with COUR Pharmaceuticals and Pfizer. 

graphic background - no.2

Build the biomarker toolbox and engage in discussions around the true markers of ‘tolerance’ for practical tolerance strategies and markers for determinants of efficacy, patient selection, and therapeutic durability with Takeda, University of Pittsburgh, Imcyse, and Anokion 

graphic background - no.3

Assess toxicity and durability of tolerance therapeutics using preclinical models to inform the frequency of administration and the persistence or loss of tolerance over time with Toleranzia and University of Helsinki

graphic background - no.4

Evaluate delivery technologies and novel approaches including CAR-Treg, mRNA-LNP, biologics, and more to propel tolerizing therapies through proof-of-concept to the clinic with Sonoma, Moderna, and Integrated Nanotherapeutics 

graphic background - no.5

Harness mechanistic models and autoimmune disease models to highlight efficacious tolerance induction across diseases including Celiac, Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, and more with GRO Bioscience, RheumaGen, NexImmune, and Parvus Therapeutics 

Who Will You Meet?

100+ senior decision makers from C-level executives to senior scientists from the leading immune tolerance biopharma companies will unite in Boston. Individuals across the whole team from discovery science, research, translational, biomarker, clinical, external innovation, and business development colleagues will unite in one room to supercharge tolerizing approaches to autoimmune disease patients in need.  

What Your Peers Have To Say:

"Presentation of novel approaches to antigen-specific tolerance some of which are currently in clinical trials. Great speakers on diverse and novel approaches to immune tolerance induction”Senior Director, Immunology, EpiVax 

epivax-companies-attending
novartis-companies-attending

"As in many occasions that I have joined the ASIT Summit I found an excellent audience, very collegial despite the competing interests of all the participants. I appreciate the openness of presenters and audience to discuss their challenges and learn from each other”Executive Director, Novartis 

“The only dedicated gathering for biotech and industry working in antigen-specific tolerance”Senior Scientist, Pfizer 

Pfizer-companies-attending
toleranzia-companies-attending

“The ASIT Summits are a great way to stay on top of the latest developments in the field and to meet and share experiences and ideas with those active in the space” – CEO, Toleranzia

“The level of sharing by the participants and the discussion facilitated by the chair were all superb”Director, Discovery Project Leader, GSK 

gsk-logo-companies-attending
Integrated_Nanotherapeutics_Logo-companies-attending

“Great content in the talks, excellent discussion and workshop sections”Director of Preclinical Development, Integrated Nanotherapeutics